GLOW vs KLOW
Research Comparison

Research Overview

GLOW and KLOW are multi-peptide research blends, each supplied as lyophilized powder in a single vial. The GLOW peptide blend holds 50MG GHK-Cu, 10MG BPC-157 and 10MG TB-500, 70MG in total. The KLOW peptide blend holds the same three in the same amounts plus 10MG KPV, 80MG in total. KPV, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH), is the only difference.

Neither blend has been studied as a mixture. A PubMed search on 8 October 2026 found no study of GLOW, KLOW or any three- or four-peptide combination of these components; the records that name GHK-Cu, BPC-157 and TB-500 together are reviews. This page covers the published work on each component and names the model behind every finding. Nearly all of it comes from cell culture and rodent models.

Composition

Amounts are from the two product pages, and the certificate summaries on those pages list labeled totals of 70MG and 80MG. GHK-Cu is the copper(II) complex of the tripeptide Gly-His-Lys, about 402 g/mol. BPC-157 is a synthetic 15-residue peptide, GEPPPGKPADDAGLV, about 1,420 g/mol. KPV is Lys-Pro-Val, C16H30N4O4, 342.43 g/mol (PubChem CID 125672).

TB-500 needs care. One doping-control analysis of material sold under that name identified the acetylated 17 to 23 fragment of thymosin beta-4, Ac-LKKTETQ (Esposito et al., 2012), about 889 g/mol, but the name is also applied to the full 43-residue protein, about 4,963 g/mol. The lot certificate decides which species a vial holds; the TB-500 research guide has the detail.

KPV is one eighth of KLOW by mass, yet from the label masses a KLOW vial holds roughly 124 µmol GHK-Cu, 29 µmol KPV, 11 µmol TB-500 (about 2 µmol as the full protein) and 7 µmol BPC-157. KPV is the second most abundant molecule in the vial, ahead of BPC-157 and TB-500 combined. For quantitative work, use the measured content on the lot certificate, which one published KLOW certificate gives for all four components.

KLOW is also listed as Capsulated KLOW, a 60-capsule format with its own per-capsule amounts and BPC-157 as an arginate salt, as listed on its product page. This comparison covers the two lyophilized vials.

Side by Side

Research Context: GLOW and the Shared Components

The GHK tripeptide readily formed a copper(II) complex and increased copper uptake into cultured hepatoma cells (Pickart et al., 1980). In lipopolysaccharide (LPS)-stimulated RAW 264.7 mouse macrophages, and in mice with LPS-induced acute lung injury, GHK-Cu lowered reactive oxygen species, TNF-alpha and IL-6 and suppressed NF-kappaB p65 and p38 MAPK signaling (Park et al., 2016). More is in the GHK-Cu research guide.

BPC-157 evidence is mostly preclinical: a 2025 systematic review included 35 preclinical studies and one clinical study, and noted the peptide lacks FDA approval (Vasireddi et al., 2025). In rat Achilles tendon explants and cultured tendon fibroblasts, BPC-157 increased explant outgrowth, fibroblast survival under hydrogen peroxide stress and fibroblast migration, with increased FAK and paxillin phosphorylation (Chang et al., 2011). See the BPC-157 research guide.

For TB-500, most biology concerns thymosin beta-4 and its actin-binding motif. Comparing the natural protein, its fragments and synthetic peptides in human umbilical vein endothelial cell migration and chick aortic arch sprouting assays, one group found the seven-residue motif matched the full protein at about 50 nM, while peptides lacking part of it were inactive (Philp et al., 2003). Findings for the full protein or the motif should not be assumed to carry over to the acetylated fragment.

The only controlled experiment pairing two of the shared components assigned 32 rats with a repaired Achilles tendon transection to control, BPC-157, TB-500 (described as synthetic thymosin beta-4) or both, for four weeks. Only the TB-500 group reached significance for maximum load to failure, and the combination showed no additive effect over either peptide alone (Biçer et al., 2026). It is one exploratory study; see the BPC-157 vs TB-500 comparison.

Research Context: KLOW and KPV

KPV is residues 11 to 13 of alpha-MSH, and its literature is preclinical throughout. In RAW 264.7 mouse macrophages stimulated with LPS and interferon-gamma, it inhibited nitric oxide production and, with maximal effect between 1 nM and 1 µM, NF-kappaB nuclear translocation, yet it did not compete for melanocortin-1 receptor binding even at 1 mM and did not raise cyclic AMP (Mandrika et al., 2001).

In mice with crystal-induced peritonitis, systemic KPV reduced polymorphonuclear leukocyte accumulation. A melanocortin 3/4 receptor antagonist did not block the effect, and it held in mice with a nonfunctional melanocortin-1 receptor; the authors concluded that KPV is unlikely to act through melanocortin receptors (Getting et al., 2003).

The largest body of KPV work concerns the intestine. In human intestinal epithelial cell lines and Jurkat T cells, nanomolar KPV inhibited NF-kappaB and MAP kinase signaling and reduced pro-inflammatory cytokine secretion. Its uptake ran through PepT1, a di- and tripeptide transporter induced in the colon during inflammatory bowel disease, and KPV in drinking water reduced DSS- and TNBS-induced colitis in mice (Dalmasso et al., 2008). PubMed lists no clinical trial of KPV. The KLOW research guide covers all four components.

Choosing Between Them for a Research Question

Because GLOW holds the same amounts of GHK-Cu, BPC-157 and TB-500 as KLOW, the pair works as an add-one-component design. Reconstituted in equal volumes, the two vials give matching nominal concentrations of the shared three, so KPV is the only planned difference and GLOW is the natural KPV-free comparator.

Readouts need care. GHK-Cu and KPV have each been reported to suppress NF-kappaB signaling in stimulated RAW 264.7 macrophages (Park et al., 2016; Mandrika et al., 2001), so GHK-Cu acts on that pathway in both arms. A KLOW versus GLOW difference shows what KPV adds on top of GHK-Cu, not what KPV does alone, and no difference may only mean a shared ceiling; a KPV-only arm separates the two. Questions about PepT1 transport or melanocortin-receptor-independent signaling point to KLOW. Where KPV would be an uncontrolled variable, GLOW is the simpler material.

Handling and Storage

Both product pages list -20°C for the lyophilized powder as shipped and 2 to 8°C after reconstitution, protected from light, with freeze/thaw cycles avoided. Let the sealed vial reach room temperature before opening so moisture does not condense on the cake, add diluent slowly down the vial wall, and swirl rather than shake.

No published data describe these mixtures in solution. In solution studies, GHK-Cu exchanged copper quickly and formed ternary complexes with glycine or histidine (Hureau et al., 2011), so chelators and amino-acid buffers can change what is in solution. Under acid, alkali and hydrogen peroxide stress, KPV yielded lys-pro-diketopiperazine as its major degradation product (Pawar et al., 2015), which argues for a near-neutral, oxidizer-free diluent in KLOW work.

Split stock into single-use aliquots, record the lot number, and keep its certificate from the COA portal with the notes. Capsulated KLOW differs: sealed capsules kept at 15 to 25°C, away from moisture and light, as listed on its product page.

Questions Researchers Ask

KLOW vs GLOW: what is the difference?

One component. Both hold 50MG GHK-Cu, 10MG BPC-157 and 10MG TB-500; KLOW adds 10MG KPV, for 80MG per vial against 70MG for GLOW, as listed on the two product pages.

Is there published research on the GLOW or KLOW peptide blend?

Not on either blend. As of 8 October 2026, PubMed holds no study of GLOW, KLOW or any three- or four-peptide mix of these components. The closest controlled experiment paired BPC-157 with TB-500 in rats and found no additive effect (Biçer et al., 2026).

Does KPV work like alpha-MSH?

Only in part. It shares anti-inflammatory activity in cell and mouse models, but it did not compete for melanocortin-1 receptor binding or raise cyclic AMP in macrophages (Mandrika et al., 2001), and its effect in mouse peritonitis held without a functional melanocortin-1 receptor (Getting et al., 2003).

Are any of the components restricted?

The WADA Prohibited List for 2026 names two, both prohibited at all times: BPC-157 in class S0, non-approved substances, and thymosin beta-4 and its derivatives, with TB-500 as the example, in class S2.3. GHK-Cu and KPV are not named. An FDA page on bulk drug substances that may present significant safety risks lists all four, GHK-Cu for injectable routes only, among former category 2 substances whose nominations the nominators withdrew.